News
Circulating biomarkers predicted melanoma survival
- Author:
- Amy Karon
Adjusted hazard ratios for overall survival were 1.75 for high versus undetectable ctDNA and 1.24 for high versus low cHGF.
News
ALUR: Alectinib topped chemo in pretreated ALK-positive NSCLC
- Author:
- Amy Karon
Median investigator-assessed, progression-free survival was 9.6 months with alectinib and 1.4 months with chemotherapy.
News
Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma
- Author:
- Amy Karon
The schedule missed its primary safety endpoint but led to fewer treatment discontinuations, dose reductions, and grade 3 toxicities than was...
News
Intrauterine therapy showed promise in XLHED
- Author:
- Amy Karon
Patients could sweat normally through up to 22 months of follow-up.
News
Anti-TNF drugs appear to lessen PD risk in IBD patients
- Author:
- Amy Karon
Among patients with inflammatory bowel disease, anti-TNF therapy led to a 78% lower rate of Parkinson’s disease.
News
Studies eye adjuvant therapy in locally advanced rectal cancer
- Author:
- Amy Karon
After a median follow-up of more than 3 years, hazard ratios for overall survival were 0.44 and 0.50, favoring adjuvant chemotherapy.
News
New regimen looks good in stage IV favorable histology Wilms
- Author:
- Amy Karon
Four-year event-free survival was 79.5% among complete responders and 89% among incomplete responders.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/October-2017/arthritis_web.jpg)
MACE risk similar across arthritis subtypes
- Author:
- Amy Karon
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
News
KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma
- Author:
- Amy Karon
CHICAGO – One-year rates of recurrence-free survival for adjuvant pembrolizumab and placebo were 75% and 61%, respectively, in a phase 3 trial of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/lung_cancer_web.jpg)
Nivolumab shows promise in early-stage resectable NSCLC
- Author:
- Amy Karon
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/April-2018/fruits_veggies_web.jpg)
Healthy lifestyle linked to better colon cancer survival
- Author:
- Amy Karon
Five-year colon cancer survival probability was 85% for highly ACS guideline–adherent patients and 76% for patients with low adherence.
News
Americans don’t know about cancer drug shortages – but want to be told
- Author:
- Amy Karon
Only 16% of respondents were aware of drug shortages, but more than 80% would want to be told about resultant substitutions with major or minor...
News
New genetic subtypes could facilitate precision medicine in DLBCL
- Author:
- Amy Karon
Multiplatform analyses identified four genetic subtypes of DLBCL that show distinct mutations, gene expression signatures, and treatment responses...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/PrematureBabyIncubator_web.jpg)
Caffeine for apnea of prematurity found safe, effective at 11 years
- Author:
- Amy Karon
At 11-year follow-up, caffeine significantly improved visuomotor, visuoperceptual, and visuospatial performance.
News
EAGLES: Smoking cessation therapy did not up cardiovascular risk
- Author:
- Amy Karon
The overall rate of major adverse cardiovascular events was less than 0.5% in a study of smokers who received one of three cessation therapies or...